Why This Webinar Matters

FDA approval may open the regulatory door, but it does not answer the core questions that shape payer acceptance, HTA review, and reimbursement outcomes.

That gap matters.

Commercial success depends not only on approval, but on whether the evidence package is built to support value, relevance, comparability, and decision-making in the real reimbursement environment.

This webinar explores what the 2025 FDA approvals reveal about that gap and what it may mean for development strategy going forward.

 

What You Will Learn

 

• • Where FDA-approved drugs in 2025 appear strong or exposed against payer and HTA evidence expectations

• • Which evidence gaps may weaken reimbursement positioning even after approval

• • What the analysis suggests for clinical development and launch planning

• • Why reimbursement thinking needs to enter the conversation earlier

• • How to challenge the assumption that approval equals market readiness

 

The Core Question

How early should reimbursement evidence shape development decisions?

This webinar is built around that question.

MARA Rating Company AG reviewed the 46 drugs approved by the FDA in 2025 to assess how well their evidence aligns with the kinds of questions payers and HTA bodies typically ask when evaluating value and reimbursement potential.

The findings raise important questions for teams responsible for evidence planning, access strategy, and launch readiness.

 

Who Should Attend

This webinar is relevant for professionals in:

 

• • Market Access

• • HEOR

• • Pricing

• • Business Development

• • Clinical Development

• • Evidence Strategy

• • Launch Planning

If your work depends on turning clinical evidence into payer value, this session will give you a more grounded view of what approval does and does not solve.

 

Why Attend Now

Pressure on evidence is increasing. Approval is no longer enough to support a strong reimbursement path on its own.

Teams that wait too long to integrate reimbursement evidence into development decisions often face the same consequences: weaker payer positioning, harder value discussions, pricing pressure, and delayed access.

This webinar offers a timely chance to step back and reassess how development and market access strategies connect.

 

About MARA Rating Company AG

MARA Rating Company AG brings a focused perspective on how evidence translates into reimbursement reality.

This webinar is part of that effort: helping stakeholders look beyond regulatory success and ask the harder question of whether a product is truly prepared for payer scrutiny and reimbursement decision-making.

 

 

Frequently Asked Questions

What is the webinar about?

This webinar examines the 46 drugs approved by the FDA in 2025 and explores how their evidence aligns with the questions payers and HTA bodies typically ask when making reimbursement decisions.

Who is this webinar for?

The session is intended for professionals in Market Access, HEOR, Pricing, Business Development, Clinical Development, and related functions involved in evidence generation, launch planning, or reimbursement strategy.

What will attendees gain from the session?

Attendees will gain a clearer understanding of the gap between regulatory approval and reimbursement readiness, along with strategic insights that can support stronger development and access planning.

Is the webinar live?

Yes. This is a live webinar taking place on Tuesday, March 24, 2026, from 6:00 PM to 7:00 PM local time.

Who is hosting the webinar?

The webinar is hosted by MARA Rating Company AG.

Why is this topic important now?

Because approval alone does not secure reimbursement. As payer and HTA expectations continue to rise, companies need to understand earlier whether their evidence will hold up in real access discussions.

Is there a registration limit?

Availability may be limited, and interest is already strong. Early registration is recommended.